• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mediwound Ltd Ord Sh (NQ: MDWD )

    18.31 -0.03 (-0.16%)
    Streaming Delayed Price Updated: 9:57 AM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,167
    Open 18.42
    Bid (Size) 18.06 (1)
    Ask (Size) 18.31 (5)
    Prev. Close 18.34
    Today's Range 18.09 - 18.42
    52wk Range 7.450 - 24.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
    From MediWound Ltd.
    Via GlobeNewswire

    Performance

    YTD
    +62.75%
    +62.75%
    1 Month
    +12.26%
    +12.26%
    3 Month
    +11.99%
    +11.99%
    6 Month
    -3.12%
    -3.12%
    1 Year
    +131.19%
    +131.19%

    More News

    Read More
    MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
    From MediWound Ltd.
    Via GlobeNewswire
    Preview: MediWound's Earnings
    Via Benzinga
    MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Report Second Quarter 2024 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces $25 Million Strategic Private Placement Financing
    From MediWound Ltd.
    Via GlobeNewswire
    Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    US Stocks Mixed; Jobs Figures Top Estimates For June
    Via Benzinga
    Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Report First Quarter 2024 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
    Via Investor Brand Network
    MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
    From MediWound Ltd.
    Via GlobeNewswire
    Earnings Scheduled For March 21, 2024
    Via Benzinga
    MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
    From MediWound Ltd.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.